Schavgoulidze, A., Lambert, J., Bobin, A., Manier, S., Perrot, A., Karlin, L., Roussel, M., Bigot, N., Benbrahim, O., Allangba, O., Rey, P., Dorvaux, V., Vignon, M., Roland, V., Garidi, R., Bastie, J., Chretien, M., Godet, S., Montes, L., Brieuc, C., Souhila, I., Vekkhof, A., Chalopin, T., Slama, B., Frenzel, L., Chalayer, E., Gardeney, H., Macro, M., Royer, B., Harel, S., Decaux, O., Arnulf, B., Merzoug, K. B., Touzeau, C., Mohty, M., Gontier, A., Moreau, P., Facon, T., Corre, J., Hulin, C., Leleu, X. (2025). Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05). Blood. https://doi.org/10.1182/blood-2025-497